nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—CYP1A2—Estropipate—osteoporosis	0.129	0.53	CbGbCtD
Phenylpropanolamine—CYP1A2—Conjugated Estrogens—osteoporosis	0.0608	0.251	CbGbCtD
Phenylpropanolamine—CYP1A2—Estradiol—osteoporosis	0.0534	0.22	CbGbCtD
Phenylpropanolamine—Pseudoephedrine—NFATC1—osteoporosis	0.0245	0.895	CrCbGaD
Phenylpropanolamine—Renal tubular necrosis—Conjugated Estrogens—osteoporosis	0.0188	0.0351	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Estropipate—osteoporosis	0.0101	0.019	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Raloxifene—osteoporosis	0.00983	0.0184	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Ethinyl Estradiol—osteoporosis	0.00823	0.0154	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Calcium Acetate—osteoporosis	0.00802	0.015	CcSEcCtD
Phenylpropanolamine—Irritability—Estropipate—osteoporosis	0.00703	0.0131	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Calcitriol—osteoporosis	0.00675	0.0126	CcSEcCtD
Phenylpropanolamine—Urinary retention—Ibandronate—osteoporosis	0.00672	0.0126	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Conjugated Estrogens—osteoporosis	0.00671	0.0125	CcSEcCtD
Phenylpropanolamine—Confusional state—Calcium Acetate—osteoporosis	0.00643	0.012	CcSEcCtD
Phenylpropanolamine—Hypotension—Calcium Acetate—osteoporosis	0.00596	0.0111	CcSEcCtD
Phenylpropanolamine—Hallucination—Etidronic acid—osteoporosis	0.00586	0.011	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Estradiol—osteoporosis	0.00571	0.0107	CcSEcCtD
Phenylpropanolamine—Irritability—Ethinyl Estradiol—osteoporosis	0.0057	0.0107	CcSEcCtD
Phenylpropanolamine—Constipation—Calcium Acetate—osteoporosis	0.00545	0.0102	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Pamidronate—osteoporosis	0.00541	0.0101	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Estradiol—osteoporosis	0.00537	0.01	CcSEcCtD
Phenylpropanolamine—Drowsiness—Calcitriol—osteoporosis	0.00533	0.00997	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Calcium Acetate—osteoporosis	0.00525	0.00982	CcSEcCtD
Phenylpropanolamine—Constipation—Ergocalciferol—osteoporosis	0.00482	0.00901	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Calcium Acetate—osteoporosis	0.0047	0.00878	CcSEcCtD
Phenylpropanolamine—Irritability—Conjugated Estrogens—osteoporosis	0.00465	0.00869	CcSEcCtD
Phenylpropanolamine—Flushing—Raloxifene—osteoporosis	0.00458	0.00857	CcSEcCtD
Phenylpropanolamine—Tension—Estropipate—osteoporosis	0.00435	0.00814	CcSEcCtD
Phenylpropanolamine—Nervousness—Estropipate—osteoporosis	0.00431	0.00806	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Calcitriol—osteoporosis	0.00427	0.00799	CcSEcCtD
Phenylpropanolamine—Confusional state—Etidronic acid—osteoporosis	0.00422	0.00789	CcSEcCtD
Phenylpropanolamine—Dizziness—Calcium Acetate—osteoporosis	0.00422	0.00788	CcSEcCtD
Phenylpropanolamine—Vomiting—Calcium Acetate—osteoporosis	0.00405	0.00758	CcSEcCtD
Phenylpropanolamine—Agitation—Calcitriol—osteoporosis	0.00383	0.00716	CcSEcCtD
Phenylpropanolamine—Nausea—Calcium Acetate—osteoporosis	0.00379	0.00708	CcSEcCtD
Phenylpropanolamine—Anxiety—Estropipate—osteoporosis	0.00376	0.00704	CcSEcCtD
Phenylpropanolamine—Irritability—Estradiol—osteoporosis	0.00372	0.00695	CcSEcCtD
Phenylpropanolamine—Anxiety—Ibandronate—osteoporosis	0.00361	0.00675	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Risedronate—osteoporosis	0.0036	0.00673	CcSEcCtD
Phenylpropanolamine—Constipation—Etidronic acid—osteoporosis	0.00358	0.00669	CcSEcCtD
Phenylpropanolamine—Flushing—Pamidronate—osteoporosis	0.00355	0.00665	CcSEcCtD
Phenylpropanolamine—Anxiety—Calcitriol—osteoporosis	0.00353	0.00661	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Etidronic acid—osteoporosis	0.00345	0.00645	CcSEcCtD
Phenylpropanolamine—Nausea—Ergocalciferol—osteoporosis	0.00334	0.00626	CcSEcCtD
Phenylpropanolamine—Insomnia—Estropipate—osteoporosis	0.00327	0.00612	CcSEcCtD
Phenylpropanolamine—Tension—Pamidronate—osteoporosis	0.00327	0.00612	CcSEcCtD
Phenylpropanolamine—Flushing—Zoledronate—osteoporosis	0.00325	0.00607	CcSEcCtD
Phenylpropanolamine—Nervousness—Pamidronate—osteoporosis	0.00324	0.00605	CcSEcCtD
Phenylpropanolamine—Somnolence—Estropipate—osteoporosis	0.00322	0.00602	CcSEcCtD
Phenylpropanolamine—Insomnia—Raloxifene—osteoporosis	0.00317	0.00593	CcSEcCtD
Phenylpropanolamine—Insomnia—Ibandronate—osteoporosis	0.00314	0.00587	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Zoledronate—osteoporosis	0.00312	0.00584	CcSEcCtD
Phenylpropanolamine—Constipation—Estropipate—osteoporosis	0.0031	0.00579	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Etidronic acid—osteoporosis	0.00308	0.00577	CcSEcCtD
Phenylpropanolamine—Insomnia—Calcitriol—osteoporosis	0.00307	0.00575	CcSEcCtD
Phenylpropanolamine—Agitation—Pamidronate—osteoporosis	0.00306	0.00573	CcSEcCtD
Phenylpropanolamine—Anxiety—Ethinyl Estradiol—osteoporosis	0.00305	0.00571	CcSEcCtD
Phenylpropanolamine—Constipation—Alendronate—osteoporosis	0.00305	0.0057	CcSEcCtD
Phenylpropanolamine—Somnolence—Calcitriol—osteoporosis	0.00302	0.00565	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Conjugated Estrogens—osteoporosis	0.00301	0.00563	CcSEcCtD
Phenylpropanolamine—Anxiety—Risedronate—osteoporosis	0.00297	0.00556	CcSEcCtD
Phenylpropanolamine—Constipation—Ibandronate—osteoporosis	0.00297	0.00555	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Alendronate—osteoporosis	0.00294	0.0055	CcSEcCtD
Phenylpropanolamine—Constipation—Calcitriol—osteoporosis	0.00291	0.00544	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—osteoporosis	0.00288	0.105	CrCbGaD
Phenylpropanolamine—Tension—Conjugated Estrogens—osteoporosis	0.00288	0.00538	CcSEcCtD
Phenylpropanolamine—Vision blurred—Zoledronate—osteoporosis	0.00287	0.00537	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ibandronate—osteoporosis	0.00286	0.00535	CcSEcCtD
Phenylpropanolamine—Tremor—Zoledronate—osteoporosis	0.00285	0.00533	CcSEcCtD
Phenylpropanolamine—Nervousness—Conjugated Estrogens—osteoporosis	0.00285	0.00532	CcSEcCtD
Phenylpropanolamine—Anxiety—Pamidronate—osteoporosis	0.00283	0.00529	CcSEcCtD
Phenylpropanolamine—Agitation—Zoledronate—osteoporosis	0.0028	0.00523	CcSEcCtD
Phenylpropanolamine—Vision blurred—Conjugated Estrogens—osteoporosis	0.00276	0.00517	CcSEcCtD
Phenylpropanolamine—Confusional state—Pamidronate—osteoporosis	0.00274	0.00513	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Estropipate—osteoporosis	0.00267	0.00499	CcSEcCtD
Phenylpropanolamine—Vomiting—Etidronic acid—osteoporosis	0.00266	0.00498	CcSEcCtD
Phenylpropanolamine—Tachycardia—Pamidronate—osteoporosis	0.00265	0.00496	CcSEcCtD
Phenylpropanolamine—Rash—Etidronic acid—osteoporosis	0.00264	0.00494	CcSEcCtD
Phenylpropanolamine—Dermatitis—Etidronic acid—osteoporosis	0.00264	0.00493	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Alendronate—osteoporosis	0.00263	0.00491	CcSEcCtD
Phenylpropanolamine—Insomnia—Risedronate—osteoporosis	0.00259	0.00484	CcSEcCtD
Phenylpropanolamine—Anxiety—Zoledronate—osteoporosis	0.00258	0.00483	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Ibandronate—osteoporosis	0.00256	0.00478	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Risedronate—osteoporosis	0.00255	0.00477	CcSEcCtD
Phenylpropanolamine—Hypotension—Pamidronate—osteoporosis	0.00254	0.00475	CcSEcCtD
Phenylpropanolamine—Constipation—Ethinyl Estradiol—osteoporosis	0.00251	0.00469	CcSEcCtD
Phenylpropanolamine—Confusional state—Zoledronate—osteoporosis	0.00251	0.00469	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Calcitriol—osteoporosis	0.0025	0.00468	CcSEcCtD
Phenylpropanolamine—Flushing—Estradiol—osteoporosis	0.0025	0.00468	CcSEcCtD
Phenylpropanolamine—Anxiety—Conjugated Estrogens—osteoporosis	0.00249	0.00465	CcSEcCtD
Phenylpropanolamine—Nausea—Etidronic acid—osteoporosis	0.00249	0.00465	CcSEcCtD
Phenylpropanolamine—Insomnia—Pamidronate—osteoporosis	0.00246	0.0046	CcSEcCtD
Phenylpropanolamine—Constipation—Risedronate—osteoporosis	0.00245	0.00458	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pamidronate—osteoporosis	0.00243	0.00454	CcSEcCtD
Phenylpropanolamine—Tachycardia—Zoledronate—osteoporosis	0.00242	0.00453	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00242	0.00452	CcSEcCtD
Phenylpropanolamine—Somnolence—Pamidronate—osteoporosis	0.00242	0.00452	CcSEcCtD
Phenylpropanolamine—Dizziness—Estropipate—osteoporosis	0.00239	0.00448	CcSEcCtD
Phenylpropanolamine—Dizziness—Alendronate—osteoporosis	0.00236	0.00441	CcSEcCtD
Phenylpropanolamine—Tachycardia—Conjugated Estrogens—osteoporosis	0.00233	0.00437	CcSEcCtD
Phenylpropanolamine—Constipation—Pamidronate—osteoporosis	0.00233	0.00435	CcSEcCtD
Phenylpropanolamine—Hypotension—Zoledronate—osteoporosis	0.00232	0.00434	CcSEcCtD
Phenylpropanolamine—Dizziness—Raloxifene—osteoporosis	0.00232	0.00434	CcSEcCtD
Phenylpropanolamine—Tension—Estradiol—osteoporosis	0.0023	0.00431	CcSEcCtD
Phenylpropanolamine—Vomiting—Estropipate—osteoporosis	0.0023	0.00431	CcSEcCtD
Phenylpropanolamine—Dizziness—Ibandronate—osteoporosis	0.0023	0.00429	CcSEcCtD
Phenylpropanolamine—Rash—Estropipate—osteoporosis	0.00228	0.00427	CcSEcCtD
Phenylpropanolamine—Dermatitis—Estropipate—osteoporosis	0.00228	0.00427	CcSEcCtD
Phenylpropanolamine—Nervousness—Estradiol—osteoporosis	0.00228	0.00426	CcSEcCtD
Phenylpropanolamine—Vomiting—Alendronate—osteoporosis	0.00227	0.00424	CcSEcCtD
Phenylpropanolamine—Rash—Alendronate—osteoporosis	0.00225	0.00421	CcSEcCtD
Phenylpropanolamine—Insomnia—Zoledronate—osteoporosis	0.00225	0.0042	CcSEcCtD
Phenylpropanolamine—Dermatitis—Alendronate—osteoporosis	0.00225	0.0042	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Pamidronate—osteoporosis	0.00224	0.00419	CcSEcCtD
Phenylpropanolamine—Hypotension—Conjugated Estrogens—osteoporosis	0.00224	0.00418	CcSEcCtD
Phenylpropanolamine—Vomiting—Raloxifene—osteoporosis	0.00223	0.00417	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Zoledronate—osteoporosis	0.00222	0.00414	CcSEcCtD
Phenylpropanolamine—Rash—Raloxifene—osteoporosis	0.00221	0.00414	CcSEcCtD
Phenylpropanolamine—Dermatitis—Raloxifene—osteoporosis	0.00221	0.00413	CcSEcCtD
Phenylpropanolamine—Somnolence—Zoledronate—osteoporosis	0.00221	0.00413	CcSEcCtD
Phenylpropanolamine—Vomiting—Ibandronate—osteoporosis	0.00221	0.00413	CcSEcCtD
Phenylpropanolamine—Tremor—Estradiol—osteoporosis	0.0022	0.00411	CcSEcCtD
Phenylpropanolamine—Rash—Ibandronate—osteoporosis	0.00219	0.00409	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ibandronate—osteoporosis	0.00219	0.00409	CcSEcCtD
Phenylpropanolamine—Insomnia—Conjugated Estrogens—osteoporosis	0.00216	0.00405	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00216	0.00404	CcSEcCtD
Phenylpropanolamine—Vomiting—Calcitriol—osteoporosis	0.00216	0.00404	CcSEcCtD
Phenylpropanolamine—Agitation—Estradiol—osteoporosis	0.00216	0.00403	CcSEcCtD
Phenylpropanolamine—Nausea—Estropipate—osteoporosis	0.00215	0.00402	CcSEcCtD
Phenylpropanolamine—Rash—Calcitriol—osteoporosis	0.00214	0.00401	CcSEcCtD
Phenylpropanolamine—Dermatitis—Calcitriol—osteoporosis	0.00214	0.004	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00213	0.00399	CcSEcCtD
Phenylpropanolamine—Somnolence—Conjugated Estrogens—osteoporosis	0.00213	0.00398	CcSEcCtD
Phenylpropanolamine—Constipation—Zoledronate—osteoporosis	0.00212	0.00397	CcSEcCtD
Phenylpropanolamine—Nausea—Alendronate—osteoporosis	0.00212	0.00396	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Risedronate—osteoporosis	0.00211	0.00394	CcSEcCtD
Phenylpropanolamine—Nausea—Raloxifene—osteoporosis	0.00208	0.0039	CcSEcCtD
Phenylpropanolamine—Nausea—Ibandronate—osteoporosis	0.00206	0.00386	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Zoledronate—osteoporosis	0.00205	0.00383	CcSEcCtD
Phenylpropanolamine—Constipation—Conjugated Estrogens—osteoporosis	0.00205	0.00383	CcSEcCtD
Phenylpropanolamine—Nausea—Calcitriol—osteoporosis	0.00202	0.00378	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pamidronate—osteoporosis	0.002	0.00375	CcSEcCtD
Phenylpropanolamine—Anxiety—Estradiol—osteoporosis	0.00199	0.00372	CcSEcCtD
Phenylpropanolamine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00194	0.00363	CcSEcCtD
Phenylpropanolamine—Confusional state—Estradiol—osteoporosis	0.00193	0.00361	CcSEcCtD
Phenylpropanolamine—Dizziness—Risedronate—osteoporosis	0.00189	0.00354	CcSEcCtD
Phenylpropanolamine—Tachycardia—Estradiol—osteoporosis	0.00187	0.00349	CcSEcCtD
Phenylpropanolamine—Vomiting—Ethinyl Estradiol—osteoporosis	0.00187	0.00349	CcSEcCtD
Phenylpropanolamine—Rash—Ethinyl Estradiol—osteoporosis	0.00185	0.00346	CcSEcCtD
Phenylpropanolamine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00185	0.00346	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Zoledronate—osteoporosis	0.00183	0.00342	CcSEcCtD
Phenylpropanolamine—Vomiting—Risedronate—osteoporosis	0.00182	0.0034	CcSEcCtD
Phenylpropanolamine—Rash—Risedronate—osteoporosis	0.0018	0.00337	CcSEcCtD
Phenylpropanolamine—Dermatitis—Risedronate—osteoporosis	0.0018	0.00337	CcSEcCtD
Phenylpropanolamine—Dizziness—Pamidronate—osteoporosis	0.0018	0.00336	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00176	0.0033	CcSEcCtD
Phenylpropanolamine—Nausea—Ethinyl Estradiol—osteoporosis	0.00174	0.00326	CcSEcCtD
Phenylpropanolamine—Insomnia—Estradiol—osteoporosis	0.00173	0.00324	CcSEcCtD
Phenylpropanolamine—Vomiting—Pamidronate—osteoporosis	0.00173	0.00323	CcSEcCtD
Phenylpropanolamine—Rash—Pamidronate—osteoporosis	0.00172	0.00321	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pamidronate—osteoporosis	0.00171	0.0032	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Estradiol—osteoporosis	0.00171	0.00319	CcSEcCtD
Phenylpropanolamine—Somnolence—Estradiol—osteoporosis	0.0017	0.00318	CcSEcCtD
Phenylpropanolamine—Nausea—Risedronate—osteoporosis	0.0017	0.00318	CcSEcCtD
Phenylpropanolamine—Dizziness—Zoledronate—osteoporosis	0.00164	0.00307	CcSEcCtD
Phenylpropanolamine—Constipation—Estradiol—osteoporosis	0.00164	0.00306	CcSEcCtD
Phenylpropanolamine—Nausea—Pamidronate—osteoporosis	0.00162	0.00302	CcSEcCtD
Phenylpropanolamine—Dizziness—Conjugated Estrogens—osteoporosis	0.00158	0.00296	CcSEcCtD
Phenylpropanolamine—Vomiting—Zoledronate—osteoporosis	0.00158	0.00295	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Estradiol—osteoporosis	0.00158	0.00295	CcSEcCtD
Phenylpropanolamine—Rash—Zoledronate—osteoporosis	0.00157	0.00293	CcSEcCtD
Phenylpropanolamine—Dermatitis—Zoledronate—osteoporosis	0.00157	0.00293	CcSEcCtD
Phenylpropanolamine—Vomiting—Conjugated Estrogens—osteoporosis	0.00152	0.00284	CcSEcCtD
Phenylpropanolamine—Rash—Conjugated Estrogens—osteoporosis	0.00151	0.00282	CcSEcCtD
Phenylpropanolamine—Dermatitis—Conjugated Estrogens—osteoporosis	0.00151	0.00282	CcSEcCtD
Phenylpropanolamine—Nausea—Zoledronate—osteoporosis	0.00148	0.00276	CcSEcCtD
Phenylpropanolamine—Nausea—Conjugated Estrogens—osteoporosis	0.00142	0.00266	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Estradiol—osteoporosis	0.00141	0.00264	CcSEcCtD
Phenylpropanolamine—Dizziness—Estradiol—osteoporosis	0.00127	0.00237	CcSEcCtD
Phenylpropanolamine—Vomiting—Estradiol—osteoporosis	0.00122	0.00228	CcSEcCtD
Phenylpropanolamine—Rash—Estradiol—osteoporosis	0.00121	0.00226	CcSEcCtD
Phenylpropanolamine—Dermatitis—Estradiol—osteoporosis	0.00121	0.00226	CcSEcCtD
Phenylpropanolamine—Nausea—Estradiol—osteoporosis	0.00114	0.00213	CcSEcCtD
Phenylpropanolamine—ADRB1—GPCR ligand binding—POMC—osteoporosis	0.000157	0.000808	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—WNT1—osteoporosis	0.000157	0.000805	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PTHLH—osteoporosis	0.000156	0.000802	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000155	0.000797	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CNR2—osteoporosis	0.000155	0.000795	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CALCA—osteoporosis	0.000154	0.000792	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—POMC—osteoporosis	0.000154	0.00079	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MGLL—osteoporosis	0.000153	0.000785	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CALCA—osteoporosis	0.000151	0.000775	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LRP5—osteoporosis	0.000149	0.000766	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TLN1—osteoporosis	0.000149	0.000765	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TLN1—osteoporosis	0.000146	0.000748	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—WNT1—osteoporosis	0.000146	0.000748	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PTHLH—osteoporosis	0.000145	0.000745	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—IDH2—osteoporosis	0.000145	0.000742	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000143	0.000735	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—P4HB—osteoporosis	0.000143	0.000733	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LRP6—osteoporosis	0.000143	0.000733	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—IL6—osteoporosis	0.000142	0.000731	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MGLL—osteoporosis	0.000142	0.000729	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTHLH—osteoporosis	0.000142	0.000728	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTH—osteoporosis	0.000139	0.000713	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LRP5—osteoporosis	0.000139	0.000712	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—POMC—osteoporosis	0.000139	0.00071	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CALCA—osteoporosis	0.000138	0.000706	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RAP1A—osteoporosis	0.000137	0.000701	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP27A1—osteoporosis	0.000136	0.000697	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CNR2—osteoporosis	0.000136	0.000695	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—ADCY5—osteoporosis	0.000135	0.00069	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ENO1—osteoporosis	0.000134	0.000686	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NFATC1—osteoporosis	0.000133	0.000684	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LRP6—osteoporosis	0.000133	0.000681	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DKK1—osteoporosis	0.000132	0.000679	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ACP5—osteoporosis	0.000132	0.000678	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTHLH—osteoporosis	0.000132	0.000676	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PSMA2—osteoporosis	0.000132	0.000676	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PSMA5—osteoporosis	0.000132	0.000676	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PKM—osteoporosis	0.000131	0.00067	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—FDPS—osteoporosis	0.000131	0.00067	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—P4HB—osteoporosis	0.000129	0.000659	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CALCA—osteoporosis	0.000128	0.000656	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—WNT1—osteoporosis	0.000127	0.000654	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—POMC—osteoporosis	0.000127	0.000653	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—P4HB—osteoporosis	0.000126	0.000645	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTH—osteoporosis	0.000125	0.000641	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CALCA—osteoporosis	0.000125	0.000641	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FGA—osteoporosis	0.000124	0.000636	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PGLS—osteoporosis	0.000124	0.000635	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPD2—osteoporosis	0.000124	0.000635	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TPI1—osteoporosis	0.000123	0.000631	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RAP1A—osteoporosis	0.000123	0.00063	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTH—osteoporosis	0.000122	0.000627	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—ADCY5—osteoporosis	0.000122	0.000627	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CNR2—osteoporosis	0.000122	0.000625	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—ADCY5—osteoporosis	0.000121	0.00062	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TLN1—osteoporosis	0.000121	0.000619	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RAP1A—osteoporosis	0.00012	0.000617	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NFATC1—osteoporosis	0.00012	0.000615	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CNR2—osteoporosis	0.000119	0.000611	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DKK1—osteoporosis	0.000119	0.00061	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000118	0.000607	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—POMC—osteoporosis	0.000118	0.000607	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—ADCY5—osteoporosis	0.000118	0.000607	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NFATC1—osteoporosis	0.000117	0.000602	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DKK1—osteoporosis	0.000116	0.000597	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CALCA—osteoporosis	0.000116	0.000595	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—P4HB—osteoporosis	0.000116	0.000593	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTHLH—osteoporosis	0.000115	0.000591	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—BMP2—osteoporosis	0.000115	0.000591	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—WNT1—osteoporosis	0.000115	0.000588	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GAPDH—osteoporosis	0.000113	0.000582	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PNP—osteoporosis	0.000113	0.000581	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ATIC—osteoporosis	0.000113	0.000581	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FGB—osteoporosis	0.000113	0.000579	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—WNT1—osteoporosis	0.000112	0.000575	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TLN1—osteoporosis	0.000112	0.000575	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGA—osteoporosis	0.000111	0.000572	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—RAP1A—osteoporosis	0.000111	0.000567	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—ADCY5—osteoporosis	0.00011	0.000563	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGA—osteoporosis	0.000109	0.000559	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PSMA5—osteoporosis	0.000109	0.000559	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PSMA2—osteoporosis	0.000109	0.000559	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—ADCY5—osteoporosis	0.000107	0.000551	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYP19A1—osteoporosis	0.000107	0.000548	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—P4HB—osteoporosis	0.000104	0.000533	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTHLH—osteoporosis	0.000104	0.000531	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—BMP2—osteoporosis	0.000104	0.000531	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IGF1—osteoporosis	0.000102	0.000522	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CALCA—osteoporosis	0.000101	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGB—osteoporosis	0.000101	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTHLH—osteoporosis	0.000101	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—BMP2—osteoporosis	0.000101	0.00052	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTH—osteoporosis	0.000101	0.000519	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RAP1A—osteoporosis	9.95e-05	0.00051	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGB—osteoporosis	9.92e-05	0.000509	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—POMC—osteoporosis	9.9e-05	0.000508	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CNR2—osteoporosis	9.86e-05	0.000506	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	9.82e-05	0.000504	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PSMA2—osteoporosis	9.79e-05	0.000502	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PSMA5—osteoporosis	9.79e-05	0.000502	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—ADCY5—osteoporosis	9.79e-05	0.000502	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFATC1—osteoporosis	9.7e-05	0.000498	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—P4HB—osteoporosis	9.67e-05	0.000496	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—OXCT1—osteoporosis	9.63e-05	0.000494	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CA2—osteoporosis	9.63e-05	0.000494	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DKK1—osteoporosis	9.63e-05	0.000494	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PSMA2—osteoporosis	9.58e-05	0.000491	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PSMA5—osteoporosis	9.58e-05	0.000491	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTH—osteoporosis	9.4e-05	0.000482	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MGLL—osteoporosis	9.39e-05	0.000481	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—WNT1—osteoporosis	9.27e-05	0.000476	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	9.24e-05	0.000474	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KL—osteoporosis	9.22e-05	0.000473	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CNR2—osteoporosis	9.16e-05	0.00047	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CALCA—osteoporosis	9.12e-05	0.000468	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	9.1e-05	0.000466	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGA—osteoporosis	9.02e-05	0.000463	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	9.02e-05	0.000462	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—POMC—osteoporosis	8.99e-05	0.000461	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DKK1—osteoporosis	8.94e-05	0.000459	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ENO1—osteoporosis	8.93e-05	0.000458	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CALCA—osteoporosis	8.93e-05	0.000458	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—POMC—osteoporosis	8.9e-05	0.000456	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—ADCY5—osteoporosis	8.89e-05	0.000456	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	8.85e-05	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PSMA2—osteoporosis	8.8e-05	0.000451	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PSMA5—osteoporosis	8.8e-05	0.000451	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6R—osteoporosis	8.77e-05	0.00045	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ADCY5—osteoporosis	8.73e-05	0.000448	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—POMC—osteoporosis	8.71e-05	0.000446	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GPX1—osteoporosis	8.7e-05	0.000446	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—WNT1—osteoporosis	8.62e-05	0.000442	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTHLH—osteoporosis	8.39e-05	0.00043	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BMP2—osteoporosis	8.39e-05	0.00043	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGA—osteoporosis	8.38e-05	0.00043	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KL—osteoporosis	8.29e-05	0.000425	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	8.26e-05	0.000424	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGB—osteoporosis	8.21e-05	0.000421	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KL—osteoporosis	8.11e-05	0.000416	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—POMC—osteoporosis	8.08e-05	0.000414	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—MTHFR—osteoporosis	8.03e-05	0.000412	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—IDH2—osteoporosis	7.98e-05	0.000409	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	7.92e-05	0.000406	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	7.92e-05	0.000406	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—POMC—osteoporosis	7.91e-05	0.000405	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6R—osteoporosis	7.88e-05	0.000404	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	7.79e-05	0.0004	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BMP2—osteoporosis	7.79e-05	0.0004	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6R—osteoporosis	7.71e-05	0.000395	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGB—osteoporosis	7.63e-05	0.000391	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP27A1—osteoporosis	7.51e-05	0.000385	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CALCA—osteoporosis	7.38e-05	0.000379	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	7.36e-05	0.000377	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	7.36e-05	0.000377	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ACP5—osteoporosis	7.3e-05	0.000374	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADCY5—osteoporosis	7.22e-05	0.00037	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.21e-05	0.00037	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	7.2e-05	0.000369	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP19A1—osteoporosis	7.14e-05	0.000366	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SPP1—osteoporosis	6.98e-05	0.000358	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CALCA—osteoporosis	6.86e-05	0.000352	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TPI1—osteoporosis	6.79e-05	0.000348	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KL—osteoporosis	6.7e-05	0.000344	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	6.69e-05	0.000343	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—POMC—osteoporosis	6.54e-05	0.000335	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADCY5—osteoporosis	6.49e-05	0.000333	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—POMC—osteoporosis	6.42e-05	0.000329	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—P4HB—osteoporosis	6.38e-05	0.000327	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	6.38e-05	0.000327	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADCY5—osteoporosis	6.35e-05	0.000326	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IRS2—osteoporosis	6.32e-05	0.000324	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SPP1—osteoporosis	6.28e-05	0.000322	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GAPDH—osteoporosis	6.26e-05	0.000321	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KL—osteoporosis	6.23e-05	0.000319	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—LEP—osteoporosis	6.18e-05	0.000317	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SPP1—osteoporosis	6.14e-05	0.000315	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—osteoporosis	6.11e-05	0.000313	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—RAP1A—osteoporosis	6.1e-05	0.000313	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—POMC—osteoporosis	6.08e-05	0.000312	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	5.93e-05	0.000304	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ESR1—osteoporosis	5.9e-05	0.000303	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ADCY5—osteoporosis	5.84e-05	0.000299	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GPX1—osteoporosis	5.82e-05	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS2—osteoporosis	5.68e-05	0.000291	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LEP—osteoporosis	5.56e-05	0.000285	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS2—osteoporosis	5.56e-05	0.000285	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IRS1—osteoporosis	5.51e-05	0.000283	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LEP—osteoporosis	5.44e-05	0.000279	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MTHFR—osteoporosis	5.37e-05	0.000275	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.32e-05	0.000273	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—POMC—osteoporosis	5.31e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ESR1—osteoporosis	5.31e-05	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	5.25e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ESR1—osteoporosis	5.19e-05	0.000266	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6R—osteoporosis	5.18e-05	0.000266	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IGF1—osteoporosis	5.11e-05	0.000262	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SPP1—osteoporosis	5.08e-05	0.000261	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IRS1—osteoporosis	4.96e-05	0.000254	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ENO1—osteoporosis	4.93e-05	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	4.88e-05	0.00025	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PSMA2—osteoporosis	4.86e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PSMA5—osteoporosis	4.86e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IRS1—osteoporosis	4.85e-05	0.000249	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—osteoporosis	4.77e-05	0.000245	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SPP1—osteoporosis	4.72e-05	0.000242	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—osteoporosis	4.67e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6R—osteoporosis	4.66e-05	0.000239	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS2—osteoporosis	4.59e-05	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IGF1—osteoporosis	4.59e-05	0.000235	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6R—osteoporosis	4.56e-05	0.000234	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—osteoporosis	4.5e-05	0.000231	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IGF1—osteoporosis	4.49e-05	0.00023	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ESR1—osteoporosis	4.29e-05	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—osteoporosis	4.29e-05	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS2—osteoporosis	4.27e-05	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—osteoporosis	4.18e-05	0.000214	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IRS1—osteoporosis	4.01e-05	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—osteoporosis	3.99e-05	0.000205	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP19A1—osteoporosis	3.94e-05	0.000202	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—osteoporosis	3.91e-05	0.0002	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—osteoporosis	3.86e-05	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6R—osteoporosis	3.77e-05	0.000193	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IRS1—osteoporosis	3.73e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—osteoporosis	3.72e-05	0.000191	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—osteoporosis	3.59e-05	0.000184	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—osteoporosis	3.51e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6R—osteoporosis	3.5e-05	0.00018	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—osteoporosis	3.45e-05	0.000177	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—osteoporosis	3.44e-05	0.000176	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADCY5—osteoporosis	3.22e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—osteoporosis	3.21e-05	0.000165	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—osteoporosis	3.07e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—osteoporosis	3.06e-05	0.000157	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—osteoporosis	2.96e-05	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—osteoporosis	2.84e-05	0.000146	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—osteoporosis	2.76e-05	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—osteoporosis	2.75e-05	0.000141	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—osteoporosis	2.7e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—osteoporosis	2.69e-05	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—osteoporosis	2.64e-05	0.000135	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—osteoporosis	2.37e-05	0.000122	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—osteoporosis	2.31e-05	0.000118	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—osteoporosis	2.23e-05	0.000115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	2.23e-05	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—osteoporosis	2.07e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—osteoporosis	2.07e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	2.07e-05	0.000106	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—osteoporosis	2.03e-05	0.000104	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—osteoporosis	1.68e-05	8.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—osteoporosis	1.56e-05	8e-05	CbGpPWpGaD
